One-year outcome following biological or mechanical valve replacement for infective endocarditis
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
PubMed
25464234
DOI
10.1016/j.ijcard.2014.10.125
PII: S0167-5273(14)02062-2
Knihovny.cz E-zdroje
- Klíčová slova
- Infective endocarditis, Surgery, Valve prosthesis,
- MeSH
- bioprotézy mikrobiologie trendy MeSH
- chirurgická náhrada chlopně mortalita trendy MeSH
- endokarditida diagnóza mortalita chirurgie MeSH
- infekce spojené s protézou diagnóza mortalita MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mortalita trendy MeSH
- prospektivní studie MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. METHODS AND RESULTS: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p=0.0009) and 25.3% vs 16.6% (p<.0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). CONCLUSIONS: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction.
American University of Beirut Medical Center Beirut Lebanon
Canberra Hospital Woden Australia
CHU Nancy Brabois Nancy France
Duke University Medical Center Durham NC USA
Flinders Medical Centre Adelaide Australia
Hopital Louis Pradel Lyon Bron France
Hospital Clinic IDIBAPS Barcelona Spain
Instituto Nacional de Cardiologia Rio de Janerio Brazil
Khon Kaen University Khon Kaen Thailand
Mater Hospitals Dublin Ireland
Medical Center Ljubljana Slovenia
Pontchaillou University Hospital Rennes France
Sanatorio de la Trinidad Mitre Buenos Aires Argentina
Citace poskytuje Crossref.org